Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ramucirumab + irinotecan as second-line therapy in metastatic/advanced gastric cancer (HGCSG1603)
jRCTs011180029Phase 2Completed
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and irinotecan in gastric adenocarcinoma and gastric cancer (GC), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Progression-free survival rate at 6 months. Started May 2018; status: completed.
02
Drugs
ramucirumabirinotecan
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on jRCTs011180029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180029.